ABINGDON HEALTH PLC

Abingdon Health offers tailored lateral flow assay development to customers working in the healthcare, veterinary, food and agriculture sectors. At Abingdon Health we take lateral flow immunoassays through a comprehensive development process from concept through to routine manufacture under our ISO 13485 and working to Good Manufacturing Practice quality management system. We have implemented a dedicated team of lateral flow assay specialists who focus on ensuring costs not only coincide with development plans. But, also the team also manages the utilisation of quality materials during development. Meaning when assay specifications are finalised for routine manufacture, costs will allow for an acceptable return on investment. To learn more about our step-by-step development process please contact us..

Abingdon Health offers fixed-cost, automated lateral flow manufacturing (works to GMP and ISO certified) with the capacity to manufacture millions of rapid tests per month. Working with customers across multiple sectors, Abingdon Health can tailor manufacturing specific to assay and customer requirements. Our experience, established supply chain and streamlined processes and procedures, coupled with the use of state-of-the-art automated lateral flow manufacturing equipment, contribute to the output of high volume batches in accordance with schedules and budget expectations.

Abingdon Health’s PCRD nucleic acid lateral flow immunoassays (NALFIA) are for use alongside isothermal amplification techniques such as LAMP or RPA. Either in a customised or standard format these rapid tests are ideal for the detection of nucleic acids for point of care molecular diagnostics. PCRD Nucleic acid lateral flow immunoassays are qualitative rapid assays designed to detect amplicons labelled with DIG/Biotin and/or FITC (or FAM)/Biotin, with the addition of a control line. Also, PCRD is a rapid, safe and sensitive alternative to ethidium bromide staining of agarose gels. Contact us to learn more about our product

AppDx, a customisable Smartphone lateral flow rapid test reader suitable for integration with existing assays or tests requiring development. AppDx combines flexible and connective mobile phone technology to provide a rapid analytical testing solution in any testing location enabling rapid decision making. The intuitive software is suitable for both Apple and Android phones removing the need for separate development for different mobile technologies.

AbC-19™ is a COVID-19 (SARS-CoV-2) neutralising antibody lateral flow test and produces results in 20 minutes from a small blood sample. This flexible, easy solution confirms the presence of IgG neutralising antibodies following COVID-19 infection or vaccination: an important factor in interpreting a person’s immunity status. This reliable and accurate (Sensitivity: 98.03%, Specificity: 99.56%) test can be used by trained professionals or trained lay users. The AbC-19™ testing solution is a powerful tool for limiting risks and helping governments, individuals and businesses make more informed decisions about COVID safety and vaccine programmes. An antibody certificate smartphone app is available upon request.